Skip to main content

Global Gene Therapy Market Size 2021-2028, Share, Growth Factors, Trends, Revenue, Competitive Landscape, Forecast

Written by Customer Service on . Posted in Mergers And Acquisitions.

Key Companies in Gene Therapy Market are Novartis AG, Spark Therapeutics, Inc., Biogen, Gilead Sciences, Inc, Amgen, Inc., Jazz Pharmaceuticals, Inc., Sarepta Therapeutics, GlaxoSmithKline plc, Other Prominent Players

Pune, India, Nov. 24, 2021 (GLOBE NEWSWIRE) — The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. Fortune Business Insights™ provided this information in a new report, titled, “Gene Therapy Market Size, Share & COVID-19 Impact Analysis, By Application (Oncology, Neurology, and Others), By Vector Type (Viral and Non-viral), By Distribution Channel (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2027.” The report further mentions that the market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period.

The emergence of the COVID-19 pandemic is taking its toll on a wide range of industries. Owing to the increasing disruption in supply & demand chain, several companies are at a complete halt. A few of them have commenced operations by following social distancing measures, as well as by lowering workforce. Our reports would provide in-depth information about the best strategy that you can select for gaining business confidence at the moment.


Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gene-therapy-market-100243


Neurology Segment to Earn High Share Fueled by High Cost of Drugs

Based on product type, the market is divided into neurology, oncology, and others. Out of these, the neurology segment earned 78.2% in terms of gene therapy market share in 2019. This growth is attributable to the increasing usage of this therapy for treating patients living with spinal muscular atrophy.

Key Players Focus on Gaining Competitive Edge by Developing New Drugs

The market houses a large number of companies that are persistently striving to bag fast-track approvals from renowned regulatory bodies. To do so, they are conducting extensive research programs and launching new drugs. Below are two of the latest industry developments:

  • July 2020: GlaxoSmithKline received license from Orchard Therapeutics for its lentiviral stable cell line technology. It will be utilized for the latter’s hematopoietic stem cell gene therapy.
  • June 2019: Bluebird Bio, Inc. received an approval for Zynteglo from the European Medicines Agency (EMA). It will be used to treat beta-thalassemia in patients belonging to the age group of 12 years and above.


For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243

The U.S. to Dominate Owing to Presence of Favorable Policies

In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions. Besides, the presence of favorable reimbursement policies and guidelines would also help in propelling the market growth here. As this type of treatment is not legal in several developing nations, industry giants are emphasizing on the U.S. for launching their products.

Europe, on the other hand, is anticipated to grow significantly backed by the adoption of unique treatment options. Asia Pacific is set to hold a comparatively lower share on account of the decreasing usage of gene therapy because of its expensive nature.


Quick Buy – Gene Therapy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100243


Fortune Business Insights™ lists out the names of all the gene therapy providers present in the global market. They are as follows:

  • Novartis AG
  • Spark Therapeutics, Inc.
  • Biogen
  • Gilead Sciences, Inc
  • Amgen, Inc.
  • Jazz Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • GlaxoSmithKline plc
  • Other Prominent Players


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.